A scientist from the University of Bristol is set to shift her focus to myeloma research, following her mother’s diagnosis of this incurable form of blood cancer. Dr. Lucy Goudswaard has been awarded a three-year Early Career Fellowship by Blood Cancer UK, which will commence in August. The fellowship is funded by the Langmuir Family Foundation and is particularly poignant for Lucy, who is driven by her personal connection to the disease.
:max_bytes(150000):strip_icc():format(jpeg)/lucy-goudswaard-061726-1-293eb90c873b4d84b46d6ecc8303bd5a.jpg)
Lucy was previously involved in cardiovascular disease research until her mother, Joy Goudswaard, was diagnosed with myeloma in 2021. Prior to her diagnosis, Joy led an active lifestyle until persistent pain led to medical examinations that revealed damage to her bones. The diagnosis has since transformed both their lives, prompting Lucy to pursue research that could make a tangible difference for those affected by this type of cancer.
In a recent statement, Lucy expressed her determination to understand better the factors contributing to myeloma development, which could ultimately prevent others from facing similar challenges. “By utilising large datasets, we will investigate what lifestyle choices may influence the onset of myeloma,” she explained in a video posted by Blood Cancer UK. Her research will specifically focus on the progression from monoclonal gammopathy of undetermined significance (MGUS), a precursor condition for myeloma.
Joy, who lives in Stroud, roughly 30 miles from Bristol, reflected on her own experience with the illness, stating that there was no family history of cancer in their family, making the diagnosis shocking and bewildering. She described her first year of treatment as “a year of hell,” which undoubtedly impacted Lucy as well. Lucy shared that she found it heartbreaking to witness her mother undergo intensive chemotherapy and a stem cell transplant.
Despite Joy’s cancer being classified as incurable, she is currently experiencing partial remission, aided by an effective therapy that has significantly decreased her cancer levels. Lucy noted that advancements in treatments for myeloma, particularly through the United Kingdom’s National Health Service, continue to improve patient outcomes.
Fiona Gebbie, a nurse affiliated with Blood Cancer UK, highlighted the predominance of myeloma as a common blood cancer, stating, “Despite meaningful progress in treatments recently, myeloma remains incurable but can be treated effectively.” She affirmed that many individuals face significant emotional challenges following diagnosis and treatment, emphasising the disease’s impact on all aspects of life.
Awareness surrounding myeloma symptoms is crucial, as Fiona pointed out that nearly half of patients in England saw their GP three or more times before receiving a diagnosis. Common symptoms like fatigue and bone pain can often be misattributed to more common ailments, underscoring the need for education among both the public and healthcare professionals.
Lucy’s research is viewed as a vital step toward increasing understanding of blood cancer, as well as developing new and improved treatments. Fiona noted that without funding for research, progress will be slow. She reinforces the necessity of supporting initiatives like Lucy’s, which are pivotal for enhancing our grasp of why blood cancers emerge.
For those affected by myeloma and other blood cancers, Blood Cancer UK continues to offer support through its dedicated services. Their confidential support line, available at 0808 2080 888 (Option 1), is a resource for emotional and practical guidance for families grappling with the challenges posed by blood cancer. Additionally, further information and resources can be accessed through their website at bloodcancer.org.uk.
Dr. Lucy Goudswaard’s commitment to blood cancer research not only reflects a personal mission but also embodies a broader quest for knowledge that could ultimately alleviate the burden of this challenging disease. Her upcoming fellowship represents hope not only for her mother but for countless others affected by myeloma.